NTRA vs PSNL
NTRA: Natera uses proprietary blood-based cell-free DNA technology to deliver personalized genetic diagnostics for oncology, prenatal screening, and organ transplant health. PSNL: A genomic testing company enabling precision oncology through ultra-sensitive liquid biopsy and tumor sequencing to detect cancer recurrence and guide personalized treatment decisions.
Side-by-side fundamentals
| Metric | NTRA | PSNL | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $264.22 | $12.47 | |
| Market cap as of 2026-07-23 | $37.9B | $1.3B | |
| PEG as of 2026-07-23 | -13.63 | n/a | |
| Net margin as of 2026-07-23 | -9.1% | -148.1% | NTRA higher |
| Gross margin as of 2026-07-23 | +65.1% | +13.7% | NTRA higher |
| Operating margin as of 2026-07-23 | -13.0% | -158.9% | NTRA higher |
| ROE as of 2026-07-23 | -15.1% | -43.5% | NTRA higher |
| ROA as of 2026-07-23 | -10.5% | -32.9% | NTRA higher |
| Debt / equity as of 2026-07-23 | 0.05 | 0.00 | PSNL lower |
| Revenue growth (YoY) as of 2026-07-23 | +36.6% | -24.7% | NTRA higher |
| Revenue CAGR (3y) SEC XBRL | +41.1% | +2.3% | NTRA higher |
| Beta as of 2026-07-23 | 1.54 | 2.29 | |
| 1-year return as of 2026-07-22 close | +88.8% | +93.9% | PSNL higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.